Valuation Update With 7 Day Price Move • Jul 07
Investor sentiment deteriorates as stock falls 17% After last week's 17% share price decline to ₹842, the stock trades at a forward P/E ratio of 28x. Average forward P/E is 33x in the Pharmaceuticals industry in India. Total returns to shareholders of 251% over the past three years. New Risk • Jul 02
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Indian stocks, typically moving 9.6% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. This is currently the only risk that has been identified for the company. Valuation Update With 7 Day Price Move • Jun 04
Investor sentiment improves as stock rises 18% After last week's 18% share price gain to ₹952, the stock trades at a forward P/E ratio of 32x. Average forward P/E is 28x in the Pharmaceuticals industry in India. Total returns to shareholders of 273% over the past three years. New Risk • May 29
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 8.9% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. This is currently the only risk that has been identified for the company. Reported Earnings • May 28
Full year 2026 earnings released: EPS: ₹25.98 (vs ₹23.35 in FY 2025) Full year 2026 results: EPS: ₹25.98 (up from ₹23.35 in FY 2025). Revenue: ₹8.39b (up 21% from FY 2025). Net income: ₹2.09b (up 11% from FY 2025). Profit margin: 25% (down from 27% in FY 2025). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 20% p.a. on average during the next 2 years, compared to a 11% growth forecast for the Pharmaceuticals industry in India. Over the last 3 years on average, earnings per share has increased by 27% per year but the company’s share price has increased by 47% per year, which means it is tracking significantly ahead of earnings growth. Ankündigung • May 27
Supriya Lifescience Limited Recommends Final Dividend Supriya Lifescience Limited announced that the Board of Directors at its meeting held on May 27, 2026 has recommended a final dividend of INR 1.00 per equity share (50% on the face value of INR 2/- each), subject to approval of shareholders at the ensuing Annual General Meeting. Ankündigung • May 20
Supriya Lifescience Limited to Report Q4, 2026 Results on May 27, 2026 Supriya Lifescience Limited announced that they will report Q4, 2026 results on May 27, 2026 Board Change • Mar 12
High number of new directors There are 5 new directors who have joined the board in the last 3 years. Independent Director Hari K was the last director to join the board, commencing their role in 2026. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model. Reported Earnings • Feb 10
Third quarter 2026 earnings released: EPS: ₹6.17 (vs ₹5.82 in 3Q 2025) Third quarter 2026 results: EPS: ₹6.17 (up from ₹5.82 in 3Q 2025). Revenue: ₹2.09b (up 13% from 3Q 2025). Net income: ₹496.8m (up 6.2% from 3Q 2025). Profit margin: 24% (down from 25% in 3Q 2025). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 25% p.a. on average during the next 3 years, compared to a 10% growth forecast for the Pharmaceuticals industry in India. Over the last 3 years on average, earnings per share has increased by 27% per year but the company’s share price has increased by 51% per year, which means it is tracking significantly ahead of earnings growth. Ankündigung • Feb 02
Supriya Lifescience Limited to Report Q3, 2026 Results on Feb 09, 2026 Supriya Lifescience Limited announced that they will report Q3, 2026 results on Feb 09, 2026 Price Target Changed • Jan 11
Price target increased by 18% to ₹940 Up from ₹800, the current price target is an average from 2 analysts. New target price is 28% above last closing price of ₹734. Stock is up 11% over the past year. The company is forecast to post earnings per share of ₹24.30 for next year compared to ₹23.35 last year. Reported Earnings • Nov 14
Second quarter 2026 earnings released: EPS: ₹6.27 (vs ₹5.71 in 2Q 2025) Second quarter 2026 results: EPS: ₹6.27 (up from ₹5.71 in 2Q 2025). Revenue: ₹2.03b (up 22% from 2Q 2025). Net income: ₹504.3m (up 9.3% from 2Q 2025). Profit margin: 25% (down from 28% in 2Q 2025). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 22% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Pharmaceuticals industry in India. Over the last 3 years on average, earnings per share has increased by 25% per year but the company’s share price has increased by 46% per year, which means it is tracking significantly ahead of earnings growth. Ankündigung • Nov 05
Supriya Lifescience Limited to Report Q2, 2026 Results on Nov 12, 2025 Supriya Lifescience Limited announced that they will report Q2, 2026 results on Nov 12, 2025 Ankündigung • Sep 24
Supriya Lifescience Limited Approves Final Dividend for the Financial Year Ended March 31, 2025 Supriya Lifescience Limited at its 17th Annual General Meeting of the Company held on September 24, 2025 approved to declare a Final Dividend of INR 1.00/- (50%) per Equity Shares of INR 2/- for the Financial Year ended March 31, 2025. Valuation Update With 7 Day Price Move • Sep 22
Investor sentiment improves as stock rises 16% After last week's 16% share price gain to ₹747, the stock trades at a forward P/E ratio of 30x. Average forward P/E is 30x in the Pharmaceuticals industry in India. Total returns to shareholders of 133% over the past three years. Ankündigung • Sep 01
Supriya Lifescience Limited, Annual General Meeting, Sep 24, 2025 Supriya Lifescience Limited, Annual General Meeting, Sep 24, 2025, at 15:00 Indian Standard Time. Reported Earnings • Aug 14
First quarter 2026 earnings released: EPS: ₹4.32 (vs ₹5.54 in 1Q 2025) First quarter 2026 results: EPS: ₹4.32 (down from ₹5.54 in 1Q 2025). Revenue: ₹1.48b (down 8.0% from 1Q 2025). Net income: ₹347.9m (down 22% from 1Q 2025). Profit margin: 24% (down from 28% in 1Q 2025). The decrease in margin was driven by lower revenue. Revenue is forecast to grow 22% p.a. on average during the next 2 years, compared to a 10% growth forecast for the Pharmaceuticals industry in India. Over the last 3 years on average, earnings per share has increased by 16% per year whereas the company’s share price has increased by 21% per year. Ankündigung • Aug 07
Supriya Lifescience Limited to Report Q1, 2026 Results on Aug 13, 2025 Supriya Lifescience Limited announced that they will report Q1, 2026 results on Aug 13, 2025 Reported Earnings • May 28
Full year 2025 earnings released: EPS: ₹23.35 (vs ₹14.80 in FY 2024) Full year 2025 results: EPS: ₹23.35 (up from ₹14.80 in FY 2024). Revenue: ₹7.06b (up 24% from FY 2024). Net income: ₹1.88b (up 58% from FY 2024). Profit margin: 27% (up from 21% in FY 2024). The increase in margin was driven by higher revenue. Revenue is forecast to grow 19% p.a. on average during the next 2 years, compared to a 10% growth forecast for the Pharmaceuticals industry in India. Over the last 3 years on average, earnings per share has increased by 10% per year but the company’s share price has increased by 26% per year, which means it is tracking significantly ahead of earnings growth. Ankündigung • May 20
Supriya Lifescience Limited to Report Q4, 2025 Results on May 27, 2025 Supriya Lifescience Limited announced that they will report Q4, 2025 results on May 27, 2025 Valuation Update With 7 Day Price Move • Apr 09
Investor sentiment deteriorates as stock falls 15% After last week's 15% share price decline to ₹667, the stock trades at a forward P/E ratio of 30x. Average forward P/E is 29x in the Pharmaceuticals industry in India. Total returns to shareholders of 48% over the past three years. New Risk • Apr 04
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Indian stocks, typically moving 9.8% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. This is currently the only risk that has been identified for the company. Valuation Update With 7 Day Price Move • Mar 21
Investor sentiment improves as stock rises 22% After last week's 22% share price gain to ₹727, the stock trades at a forward P/E ratio of 33x. Average forward P/E is 30x in the Pharmaceuticals industry in India. Total returns to shareholders of 55% over the past three years. Ankündigung • Mar 10
Supriya Lifescience Limited Approves the Appointment of Prachi Sathe as Company Secretary and Compliance Officer Supriya Lifescience Limited Board of Directors at their meeting held on March 10,2025 inter alia considered and approved the following businesses: Appointment of Ms. Prachi Sathe bearing Membership No. A-70252 as Company Secretary and Compliance Officer of the Company with effect from March 10, 2025, on the basis of recommendations received from the Nomination and Remuneration Committee of the Company. Ms. Prachi Sathe (ACS 70252) is a qualified Company Secretary. She is an Associate Member of the Institute of Company Secretaries of India (ICSI). She has completed her post graduation in law and graduation in Commerce from the University of Mumbai. She has an experience of 8 years in Secretarial and Compliance function. Valuation Update With 7 Day Price Move • Feb 04
Investor sentiment improves as stock rises 23% After last week's 23% share price gain to ₹765, the stock trades at a forward P/E ratio of 34x. Average forward P/E is 31x in the Pharmaceuticals industry in India. Total returns to shareholders of 66% over the past three years. Ankündigung • Feb 01
Supriya Lifescience Limited Announces Board Changes Supriya Lifescience Limited announced that Mr. Kedar Karmarkar and Mr. Bhairav Chokshi, Independent Directors of the Company, has completed their 2 terms of 5 years as Independent Directors on February 1, 2025 and accordingly they will cease to be Directors and Independent Directors of the Company with effect from February 1, 2025. In continuation of Outcome of the Board Meeting dated January 24, 2025, the company announced that Dr. Ganapati Dadasaheb Yadav and Dr. Sunil Subhash Bhagwat were appointed as an Additional Directors - Non-Executive, Independent Category, with effect from January 24, 2025. Reported Earnings • Jan 25
Third quarter 2025 earnings released: EPS: ₹5.82 (vs ₹3.70 in 3Q 2024) Third quarter 2025 results: EPS: ₹5.82 (up from ₹3.70 in 3Q 2024). Revenue: ₹1.88b (up 34% from 3Q 2024). Net income: ₹467.8m (up 57% from 3Q 2024). Profit margin: 25% (up from 21% in 3Q 2024). The increase in margin was driven by higher revenue. Revenue is forecast to grow 20% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Pharmaceuticals industry in India. Over the last 3 years on average, earnings per share has increased by 1% per year but the company’s share price has increased by 15% per year, which means it is tracking significantly ahead of earnings growth. Ankündigung • Jan 24
Supriya Lifescience Limited Announces Resignation of Shweta Shivdhari Singh as Company Secretary & Compliance Officer Supriya Lifescience Limited announced that Ms. Shweta Shivdhari Singh, vide her letter dated January 24, 2025, has tendered her resignation from the post of Company Secretary & Compliance Officer and a Key Managerial Personnel (KMP) of the Company to pursue new career opportunity with effect from closing of business hours of January 29, 2025. Further, she has confirmed that there are no other material reasons for the resignation other than those provided in her resignation letter. Ankündigung • Jan 16
Supriya Lifescience Limited to Report Q3, 2025 Results on Jan 24, 2025 Supriya Lifescience Limited announced that they will report Q3, 2025 results on Jan 24, 2025 Valuation Update With 7 Day Price Move • Nov 22
Investor sentiment improves as stock rises 25% After last week's 25% share price gain to ₹802, the stock trades at a forward P/E ratio of 38x. Average forward P/E is 33x in the Pharmaceuticals industry in India. Total returns to shareholders of 190% over the past year. Reported Earnings • Oct 29
Second quarter 2025 earnings released: EPS: ₹5.71 (vs ₹2.97 in 2Q 2024) Second quarter 2025 results: EPS: ₹5.71 (up from ₹2.97 in 2Q 2024). Revenue: ₹1.69b (up 20% from 2Q 2024). Net income: ₹461.5m (up 93% from 2Q 2024). Profit margin: 27% (up from 17% in 2Q 2024). The increase in margin was driven by higher revenue. Revenue is forecast to grow 20% p.a. on average during the next 2 years, compared to a 11% growth forecast for the Pharmaceuticals industry in India. Ankündigung • Oct 21
Supriya Lifescience Limited to Report Q2, 2025 Results on Oct 28, 2024 Supriya Lifescience Limited announced that they will report Q2, 2025 results on Oct 28, 2024 Declared Dividend • Sep 07
Dividend increased to ₹0.80 Dividend of ₹0.80 is 33% higher than last year. Ex-date: 20th September 2024 Payment date: 27th October 2024 Dividend yield will be 0.1%, which is lower than the industry average of 0.8%. Sustainability & Growth Dividend is covered by earnings (5% earnings payout ratio) but the company has no free cash flows available, indicating it may be using cash reserves or debt to pay the dividend. The dividend has increased by an average of 15% per year over the past 2 years and payments have been stable during that time. EPS is expected to grow by 17% over the next year, which should provide support to the dividend and adequate earnings cover. Ankündigung • Sep 04
Supriya Lifescience Limited, Annual General Meeting, Sep 27, 2024 Supriya Lifescience Limited, Annual General Meeting, Sep 27, 2024, at 15:00 Indian Standard Time. Reported Earnings • Aug 11
First quarter 2025 earnings released: EPS: ₹5.54 (vs ₹3.54 in 1Q 2024) First quarter 2025 results: EPS: ₹5.54 (up from ₹3.54 in 1Q 2024). Revenue: ₹1.63b (up 23% from 1Q 2024). Net income: ₹446.4m (up 57% from 1Q 2024). Profit margin: 27% (up from 22% in 1Q 2024). The increase in margin was driven by higher revenue. Revenue is forecast to grow 18% p.a. on average during the next 2 years, compared to a 10% growth forecast for the Pharmaceuticals industry in India. Ankündigung • Aug 04
Supriya Lifescience Limited to Report Q1, 2025 Results on Aug 10, 2024 Supriya Lifescience Limited announced that they will report Q1, 2025 results at 4:00 PM, Indian Standard Time on Aug 10, 2024 Reported Earnings • May 29
Full year 2024 earnings released: EPS: ₹14.80 (vs ₹11.17 in FY 2023) Full year 2024 results: EPS: ₹14.80 (up from ₹11.17 in FY 2023). Revenue: ₹5.81b (up 26% from FY 2023). Net income: ₹1.19b (up 33% from FY 2023). Profit margin: 21% (in line with FY 2023). Revenue is forecast to grow 18% p.a. on average during the next 2 years, compared to a 10% growth forecast for the Pharmaceuticals industry in India. Ankündigung • May 22
Supriya Lifescience Limited to Report Q4, 2024 Results on May 28, 2024 Supriya Lifescience Limited announced that they will report Q4, 2024 results on May 28, 2024 Valuation Update With 7 Day Price Move • Apr 04
Investor sentiment improves as stock rises 17% After last week's 17% share price gain to ₹389, the stock trades at a forward P/E ratio of 22x. Average forward P/E is 29x in the Pharmaceuticals industry in India. Total returns to shareholders of 89% over the past year. Board Change • Apr 01
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 5 experienced directors. 4 highly experienced directors. Independent Director Neelam Arora was the last director to join the board, commencing their role in 2021. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Price Target Changed • Feb 15
Price target increased by 47% to ₹401 Up from ₹272, the current price target is provided by 1 analyst. New target price is 7.9% above last closing price of ₹372. Stock is up 83% over the past year. The company is forecast to post earnings per share of ₹14.30 for next year compared to ₹11.16 last year. Valuation Update With 7 Day Price Move • Feb 14
Investor sentiment improves as stock rises 16% After last week's 16% share price gain to ₹360, the stock trades at a forward P/E ratio of 21x. Average forward P/E is 30x in the Pharmaceuticals industry in India. Total returns to shareholders of 87% over the past year. Reported Earnings • Feb 08
Third quarter 2024 earnings released: EPS: ₹3.70 (vs ₹1.18 in 3Q 2023) Third quarter 2024 results: EPS: ₹3.70 (up from ₹1.18 in 3Q 2023). Revenue: ₹1.43b (up 36% from 3Q 2023). Net income: ₹297.9m (up 213% from 3Q 2023). Profit margin: 21% (up from 9.1% in 3Q 2023). The increase in margin was driven by higher revenue. Revenue is forecast to grow 13% p.a. on average during the next 2 years, compared to a 10% growth forecast for the Pharmaceuticals industry in India. Ankündigung • Jan 31
Supriya Lifescience Limited to Report Q3, 2024 Results on Feb 07, 2024 Supriya Lifescience Limited announced that they will report Q3, 2024 results on Feb 07, 2024 Buy Or Sell Opportunity • Jan 23
Now 21% undervalued Over the last 90 days, the stock has risen 23% to ₹299. The fair value is estimated to be ₹378, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has been flat over the last year. Earnings per share has declined by 18%. Revenue is forecast to grow by 16% in a year. Earnings are forecast to grow by 24% in the next year. Buying Opportunity • Jan 10
Now 20% undervalued Over the last 90 days, the stock is up 20%. The fair value is estimated to be ₹376, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has been flat over the last year. Earnings per share has declined by 18%. Revenue is forecast to grow by 16% in a year. Earnings is forecast to grow by 24% in the next year. Valuation Update With 7 Day Price Move • Dec 27
Investor sentiment improves as stock rises 16% After last week's 16% share price gain to ₹314, the stock trades at a forward P/E ratio of 20x. Average forward P/E is 29x in the Pharmaceuticals industry in India. Total returns to shareholders of 36% over the past year. Valuation Update With 7 Day Price Move • Nov 30
Investor sentiment improves as stock rises 16% After last week's 16% share price gain to ₹291, the stock trades at a forward P/E ratio of 19x. Average forward P/E is 28x in the Pharmaceuticals industry in India. Total returns to shareholders of 16% over the past year. Reported Earnings • Nov 11
Second quarter 2024 earnings released: EPS: ₹2.97 (vs ₹2.10 in 2Q 2023) Second quarter 2024 results: EPS: ₹2.97 (up from ₹2.10 in 2Q 2023). Revenue: ₹1.40b (up 25% from 2Q 2023). Net income: ₹238.8m (up 42% from 2Q 2023). Profit margin: 17% (up from 15% in 2Q 2023). The increase in margin was driven by higher revenue. Revenue is forecast to grow 17% p.a. on average during the next 2 years, compared to a 10% growth forecast for the Pharmaceuticals industry in India. Ankündigung • Oct 28
Supriya Lifescience Limited to Report Q2, 2024 Results on Nov 07, 2023 Supriya Lifescience Limited announced that they will report Q2, 2024 results on Nov 07, 2023 Ankündigung • Sep 08
Supriya Lifescience Limited, Annual General Meeting, Sep 29, 2023 Supriya Lifescience Limited, Annual General Meeting, Sep 29, 2023, at 15:00 Indian Standard Time. Agenda: To receive, consider, approve and adopt the Audited Financial Statements of the Company for the financial year ended March 31, 2023 and the reports of the Board of Directors and Auditors thereon; to consider declare a Final Dividend on Equity Shares for the Financial Year ended March 31, 2023; to consider and appoint a Director in place of Ms. Shivani Satish Wagh who retires by rotation and, being eligible, offers herself for re-appointment; and to consider and ratify the remuneration of Cost Auditors for the FY 2023-2024. Reported Earnings • Aug 04
First quarter 2024 earnings released: EPS: ₹3.54 (vs ₹3.14 in 1Q 2023) First quarter 2024 results: EPS: ₹3.54 (up from ₹3.14 in 1Q 2023). Revenue: ₹1.35b (up 33% from 1Q 2023). Net income: ₹285.1m (up 13% from 1Q 2023). Profit margin: 21% (down from 25% in 1Q 2023). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 17% p.a. on average during the next 2 years, compared to a 10% growth forecast for the Pharmaceuticals industry in India. Ankündigung • Jul 29
Supriya Lifescience Limited to Report Q1, 2024 Results on Aug 03, 2023 Supriya Lifescience Limited announced that they will report Q1, 2024 results on Aug 03, 2023 Ankündigung • May 20
Supriya Lifescience Limited to Report Q4, 2023 Results on May 26, 2023 Supriya Lifescience Limited announced that they will report Q4, 2023 results on May 26, 2023 Recent Insider Transactions • Apr 05
Founder recently bought ₹2.5m worth of stock On the 31st of March, Satish Wagh bought around 13k shares on-market at roughly ₹190 per share. This transaction amounted to less than 1% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. This was Satish's only on-market trade for the last 12 months. Recent Insider Transactions • Apr 03
Founder recently bought ₹2.5m worth of stock On the 29th of March, Satish Wagh bought around 14k shares on-market at roughly ₹178 per share. This transaction amounted to less than 1% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. This was Satish's only on-market trade for the last 12 months. Reported Earnings • Feb 15
Third quarter 2023 earnings released: EPS: ₹1.18 (vs ₹4.93 in 3Q 2022) Third quarter 2023 results: EPS: ₹1.18 (down from ₹4.93 in 3Q 2022). Revenue: ₹1.08b (down 7.9% from 3Q 2022). Net income: ₹95.2m (down 76% from 3Q 2022). Profit margin: 8.8% (down from 34% in 3Q 2022). The decrease in margin was primarily driven by higher expenses. Ankündigung • Feb 07
Supriya Lifescience Limited to Report Q3, 2023 Results on Feb 14, 2023 Supriya Lifescience Limited announced that they will report Q3, 2023 results on Feb 14, 2023 Ankündigung • Nov 03
Supriya Lifescience Limited to Report Q2, 2023 Results on Nov 10, 2022 Supriya Lifescience Limited announced that they will report Q2, 2023 results on Nov 10, 2022 Ankündigung • Sep 28
Supriya Lifescience Limited Announces Executive Changes Supriya Lifescience Limited informed that Dr. Shireesh Ambhaikar, Chief Executive Officer and a Key Managerial Personnel of the company, has resigned from the position due to his personal reasons and requested, inter alia, for acceptance of his resignation and relieving him by September 30, 2022 and which has been accepted by the Board in its meeting held on September 27, 2022. However, Dr. Shireesh Ambhaikar has agreed to extend his services on a retainership basis for a period of 2 (two) years effective October 1, 2022 where he will be designated as Technical Head for certain projects of Supriya Lifescience Limited to ensure their timely execution, knowledge transfer and smooth transition to his successor, who will be joining the company on October 3, 2022. The Board has in its meeting held on September 27, 2022 approved the appointment of Mr. Rajeev Kumar Jain as Chief Executive Officer and Key Managerial Personnel of the Company, who will be joining on October 3, 2022 to take Supriya on the next phase of its growth journey. Seasoned professional having worked in reputed Corporates in API business with over 35+ years of experience covering manufacturing, general management and business. Ankündigung • Aug 23
Supriya Lifescience Limited, Annual General Meeting, Sep 16, 2022 Supriya Lifescience Limited, Annual General Meeting, Sep 16, 2022, at 15:00 Indian Standard Time. Reported Earnings • Aug 14
First quarter 2023 earnings released: EPS: ₹3.14 (vs ₹6.51 in 1Q 2022) First quarter 2023 results: EPS: ₹3.14 (down from ₹6.51 in 1Q 2022). Revenue: ₹1.04b (down 20% from 1Q 2022). Net income: ₹252.5m (down 47% from 1Q 2022). Profit margin: 24% (down from 37% in 1Q 2022). The decrease in margin was driven by lower revenue. Ankündigung • Aug 07
Supriya Lifescience Limited to Report Q1, 2023 Results on Aug 12, 2022 Supriya Lifescience Limited announced that they will report Q1, 2023 results on Aug 12, 2022 Reported Earnings • May 23
Full year 2022 earnings released: EPS: ₹18.86 (vs ₹16.92 in FY 2021) Full year 2022 results: EPS: ₹18.86 (up from ₹16.92 in FY 2021). Revenue: ₹5.30b (up 36% from FY 2021). Net income: ₹1.52b (up 23% from FY 2021). Profit margin: 29% (down from 32% in FY 2021). The decrease in margin was driven by higher expenses. Ankündigung • May 21
Supriya Lifescience Limited Recommends the Final Dividend Supriya Lifescience Limited Recommended the Final Dividend of INR 0.60 per equity share (face value of INR 2 each) subject to approval of shareholders in the upcoming Annual General Meeting. Valuation Update With 7 Day Price Move • May 20
Investor sentiment improved over the past week After last week's 17% share price gain to ₹380, the stock trades at a trailing P/E ratio of 18.5x. Average trailing P/E is 21x in the Pharmaceuticals industry in India. Ankündigung • May 14
Supriya Lifescience Limited to Report Q4, 2022 Results on May 20, 2022 Supriya Lifescience Limited announced that they will report Q4, 2022 results on May 20, 2022 Board Change • Apr 27
High number of new directors There are 5 new directors who have joined the board in the last 3 years. Independent Director Neelam Arora was the last director to join the board, commencing their role in 2021. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model. Reported Earnings • Jan 23
Third quarter 2022 earnings: Revenues and EPS in line with analyst expectations Third quarter 2022 results: EPS: ₹4.93 (down from ₹6.51 in 3Q 2021). Revenue: ₹1.22b (down 5.9% from 3Q 2021). Net income: ₹396.4m (down 17% from 3Q 2021). Profit margin: 32% (down from 37% in 3Q 2021). Revenue was in line with analyst estimates. Board Change • Dec 29
High number of new directors There are 5 new directors who have joined the board in the last 3 years. Independent Director Neelam Arora was the last director to join the board, commencing their role in 2021. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model. 
